Study #2024-0032
A phase I study of Decitabine, Lisaftoclax, and Olverembatinib in patients with advanced chronic myeloid leukemia and philadelphia chromosome-positive acute myeloid leukemia.
MD Anderson Study Status
Enrolling
Treatment Agent
Decitabine, Listaftoclax, Olverembatinib
Description
To find the recommended doses of lisaftoclax and olverembatinib that can be given in combination with decitabine to participants with advanced CML and Ph+ AML.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Chronic Myeloid Leukemia, Philadelphia Chromosome-Positive Acute Myeloid Leukemia
Study phase:
Phase I
Physician name:
Nicholas Short
Department:
Leukemia
For general questions about clinical trials:
1-844-952-3934
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.